Technetium Tc 99m Oxidronate
Generic Name: technetium tc 99m oxidronate
Brand Names:
Technescan Hdp
DESCRIPTION Drug Characteristics Technescan™ HDP (kit for the preparation of technetium Tc 99m oxidronate injection) is a radioactive diagnostic drug for intravenous use after radiolabeling with sodium pertechnetate Tc 99m injection.
Overview
DESCRIPTION Drug Characteristics Technescan™ HDP (kit for the preparation of technetium Tc 99m oxidronate injection) is a radioactive diagnostic drug for intravenous use after radiolabeling with sodium pertechnetate Tc 99m injection.
Uses
INDICATIONS AND USAGE Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in adult and pediatric patients.
Dosage
DOSAGE AND ADMINISTRATION Radiation Safety – Drug Handling After radiolabeling of Technescan HDP, the reaction vial contains Technetium Tc 99m Oxidronate Injection. Handle Technetium Tc 99m Oxidronate Injection with appropriate safety measures to minimize radiation exposure. (See PRECAUTIONS, General .) Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Technetium Tc 99m Oxidronate Injection. Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
Side Effects
ADVERSE REACTIONS The following adverse reactions associated with the use of Technescan HDP have been reported: hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting, and injection site reactions.
Interactions
Drug Interactions The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation).
Warnings
WARNINGS Technetium Tc 99m oxidronate may cause life-threatening hypersensitivity reactions. Have cardiopulmonary resuscitation equipment and personnel available and monitor all patients for hypersensitivity reactions. (See ADVERSE REACTION S .) Technetium Tc 99m oxidronate is known to complex cations such as calcium. Particular caution should be used with patients who have or who may be predisposed to hypocalcemia. The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. CONTRAINDICATIONS None known.
Pregnancy
Pregnancy Animal reproduction studies have not been conducted with technetium Tc 99m oxidronate. It is also not known whether technetium Tc 99m oxidronate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. All radiopharmaceuticals, including Tehnescan HDP, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
Storage
HOW SUPPLIED Technescan HDP (kit for the preparation of technetium Tc 99m oxidronate injection) contains 3.15 mg oxidronate sodium as a white lyophilized powder in a multiple-dose vial. Technescan HDP is available as: • 5 vials per carton (NDC 69945-091-20) • 30 vials per carton (NDC 69945-091-40) Before radiolabeling, store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
Frequently Asked Questions
What is Technetium Tc 99m Oxidronate used for?▼
INDICATIONS AND USAGE Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in adult and pediatric patients.
What are the side effects of Technetium Tc 99m Oxidronate?▼
ADVERSE REACTIONS The following adverse reactions associated with the use of Technescan HDP have been reported: hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting, and injection site reactions.
Can I take Technetium Tc 99m Oxidronate during pregnancy?▼
Pregnancy Animal reproduction studies have not been conducted with technetium Tc 99m oxidronate. It is also not known whether technetium Tc 99m oxidronate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. All radiopharmaceuticals, including Tehnescan HDP, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
What are the important warnings for Technetium Tc 99m Oxidronate?▼
WARNINGS Technetium Tc 99m oxidronate may cause life-threatening hypersensitivity reactions. Have cardiopulmonary resuscitation equipment and personnel available and monitor all patients for hypersensitivity reactions. (See ADVERSE REACTION S .) Technetium Tc 99m oxidronate is known to complex cations such as calcium. Particular caution should be used with patients who have or who may be predisposed to hypocalcemia. The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. CONTRAINDICATIONS None known.
Related Medications
Epidermophyton Floccosum
epidermophyton floccosum
Dosage form: SOLUTION. Route: INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: EPIDERMOPHYTON FLOCCOSUM (.05 g/mL). Category: BLA.
Glimepiride
glimepiride
Sulfonylurea [EPC]
11 DESCRIPTION Glimepiride tablets, USP are an oral sulfonylurea that contains the active ingredient glimepiride. Chemically, glimepiride is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white or almost white powder and is practically insoluble in water.
Aesculus Hippocastanum, Equisetum Hyemale, Hydrastis Canadensis, Hydrocotyle Asiatica, Magnesia Muriatica, Linum Usitatissimum, Passiflora Incarnata, Solidago Virgaurea, Thuja Occidentalis, Fumaria Officinalis, Ononis Spinosa
aesculus hippocastanum, equisetum hyemale, hydrastis canadensis, hydrocotyle asiatica, magnesia muriatica, linum usitatissimum, passiflora incarnata, solidago virgaurea, thuja occidentalis, fumaria officinalis, ononis spinosa
Non-Standardized Food Allergenic Extract [EPC]
PURPOSE: Aesculus Hippocastanum – Detox of colon, portal system,* Equisetum Hyemale – bladder, kidneys,* Hydrastis Canadensis – sinuses, lungs,* Hydrocotyle Asiatica – lymph, skin, connective tissue,* Magnesia Muriatica - liver,* Linum Usitatissimum – mucous membranes,* Passiflora Incarnata – nervous system,* Solidago Virgaurea – bladder kidneys,* Thuja Occidentalis – intestine, skin,* Fumaria Officinalis – liver, gallbladder,* Ononis Spinosa – urinary system.*
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.